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Abstract
Background: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the
mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination
responses in murine models of lung cancer.
Principal Findings: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor
activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the
frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment
led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNc, perforin and granzyme (iv)
CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi)
reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10)
expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections
showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC
depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors
from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following
MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their
primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this
group had 20 fold reductions in tumor burden compared to controls.
Significance: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad
applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against
tumors where MDSC play a role in tumor immune evasion.
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Introduction
Lung cancer remains a daunting health problem with more
than 1.1 million deaths attributed to lung cancer worldwide
annually [1]. With the existing therapeutic efforts the long term
survival for lung cancer patients remains low, thus new therapeutic
strategies are needed. Although cancer immunotherapy offers an
attractive therapeutic option, activation of the immune system
alone is not sufficient for antitumor activity. We anticipate that
combined therapies that target pathways of immune activation
and mechanisms of immune suppression will be necessary to
combat lung cancer. The tumor microenvironment consists of
tumor cells, stroma, blood vessels, immune infiltrates and the
extracellular matrix. Genetic alterations in oncogenes and tumor
suppressor genes or epigenetic changes in the tumor that modulate
tumor growth and invasion into the surrounding tissue orchestrate
the persistence of inflammatory infiltrates. These cellular infiltrates
modulate tumor development and progression. The tumor
infiltrates vary by size and composition in diverse tumor types
and at different stages of tumor development. The tumor
programs the cellular infiltrates to sustain a dysregulated in-
flammation that is hypo responsive to the tumor. Contributing to
the cellular inflammatory infiltrates are myeloid derived suppres-
sor cells (MDSC) that negatively modulate immune responses and
promote tumor progression and metastases [2].
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MDSC are a heterogeneous population of immature myeloid
cells that consists of myeloid progenitors and precursors of
macrophages, granulocytes and dendritic cell (DC) [3]. In mice,
MDSC are identified by antibodies that detect cell surface
expression of Gr1 and CD11b. Increases in the number of MDSC
evoke strong natural suppressive activity in cancer patients [4,5] or
tumor-bearing mice [4,6,7]. It has been demonstrated that
Gr1+CD11b+ immune suppressive cells are capable of inhibiting
the T cell proliferative response induced by alloantigens [8], CD3
ligation [9], or various mitogens [10,11], and can also inhibit IL-2
utilization [12] as well as NK cell activity [5,13]. These studies
indicate that progressive tumor growth is associated with the
down-regulation of T cell responses and that the MDSC are
involved in negative immunoregulatory mechanisms. In murine
tumor models, increases in MDSC in the tumors, spleens, bone
marrow and blood downregulates T cell responses [2]. Consid-
ering the above information, it is important to understand the
impact of MDSC depletion in the modulation of immune
responses in lung cancer.
In this study, we evaluated the contribution of the Gr1 or Ly6G
expressing myelomonocytic cells on 3LL tumor growth and
therapeutic vaccination responses in C57BL/6 mice. Our results
demonstrate that MDSC depletion increased APC activity and
augmented the frequency and activity of NK and T cells effectors
that led to reduced tumor growth, enhanced therapeutic
vaccination responses and conferred immunological memory.
Our data provides support for the development of agents that
target MDSC for combined immune based therapeutic ap-
proaches in lung cancer.
Materials and Methods
Cell Lines and Reagents
The murine Lewis lung carcinoma (3LL, H-2b, also known as
LLC, ATCC CRL-1642) obtained from American Type Culture
Collection (Manassas, VA), DC2.4 (kind gift from K. L. Rock
Dana Farber Cancer Institute, Boston, Mass.) [14] and the
b galactosidase reporter T cell hybridoma (B3Z) which recognizes
the kb Class I molecule and an ovalbumen (OVA) peptide, SL8
(SIINFEKL) was obtained from N Shastri (UC Berkeley, CA) [15]
were used in these studies. 3LL-OVA cells were generated by
transfecting 3LL parental cells with the OVA constructs obtained
from Dr. Frelinger (University of Rochester, NY). The expression
vectors encoding either the full-length Ova or truncated Ova-(138-
386) (Ova non-secretory) were transfected using Lipofectin
(GIBCO/BRL) according to the manufacturer’s instructions.
Selection with the appropriate drug was performed as described
[16]. Stable 3LL-OVA transfectants were selected following OVA
ELISA of cell lysates and cloned by limited dilution in 96-well
plates. For the experiments described in this study we used the
3LL-OVA that expressed the truncated Ova-(138-386). The
culture medium (CM) contained RPMI 1640 (Irvine Scientific,
Santa Ana, CA) supplemented with 10% fetal bovine serum
(Gemini Bioproducts, Calabasas, CA), penicillin (100 units/ml),
streptomycin (0.1 mg/ml), and 2 mmol/L glutamine (JRH
Biosciences, Lenexa, KS). Fluorescein isothiocyanate-, phycoery-
thrin-, allophycocyanin-, PerCP- or APC-Cy7-conjugated anti-
mouse mAbs to CD3 (145-2C11), CD4 (RM4-5), CD69 (H1.2F3)
and CD8a (53-6.7) were purchased from BD Biosciences (San
Diego, CA). Fluorescent-conjugated mouse Abs: anti-CD49b, anti-
CD11c, anti-CD69, anti-CD44, anti-perforin, anti-granzyme,
anti-IL10, anti-IFNc, anti EpCam and anti-CD107a were from
eBioscience (San Diego, CA) and anti-Gr1, anti-CD45 and anti-
CD11b were from Biolegend (San Diego, CA). Neutralizing Abs
to: Gr1 (RB6-8C5), Ly6G (1A8) were from BioXCell (West
Lebanon, NH) and Keratin was from Sigma. IL-2, IFNc, IL-12,
IL-10 and TNFa were quantified with cytokine specific ELISA kits
(eBioScience). Sensitivity: IL-2 (3 pg/ml), IFNc (3 pg/ml), IL-12
(3–5 pg/ml), IL-10 (30 pg/ml) and TNFa (8 pg/ml). Ovalbumen
protein and Bradford protein quantification dye was obtained
from Sigma (St. Louis, MO). Tissue digestion buffer consisted of
[0.2 mg/ml of Collagenase A (Boehringer Mannheim/Roche,
Indianapolis, IN), DNAse 25 U/ml (Sigma), and 0.3 U/ml of
Dispase (Invitrogen, Carlsbad, CA) in RPMI. T cell purification
columns were purchased from R&D (Minneapolis) and MDSC
magnetic separation Ab was from Miltenyi Biotech (Auburn, CA).
RNA isolation kit was from Qiagen (Valencia, CA) and cDNA kit
from BioRad (Hercules, CA) and real time PCR primers were
from IDT (Coralville, Iowa). Carboxyfluorescein succinimidyl
ester (CFSE) was obtained from Invitrogen.
Cell Culture
Cells (3LL, DC 2.4, B3Z and 3LL-OVA) were routinely
cultured in Corning T75 cm2 tissue culture flask in humidified
atmosphere containing 5% CO2 in air in culture medium (CM).
The cell lines were Mycoplasma and murine viral pathogen free.
The cell lines were used up to the 10th passage. Bone marrow (BM)
was harvested by flushing the femurs of C57BL/6 mice with
RPMI supplemented with 20% fetal bovine medium (RP-20). The
pooled marrow cells were plated in RP-20 supplemented with 1%
penicillin-streptomycin and cultured for 72 hrs on flasks coated
with 2% gelatin (Sigma, St Louis MO). Non-adherent cells were
washed off and adherent cells expanded in RP-20. Following the
culture period (11–14 days), single cell suspensions of cultured
BMA cells were stained for cell surface markers for: monocytes
(CD11b+), macrophages (CD11b+/F4/80+), stromal cells
(CD452/CD11b2/CD44+/CD342), DC (CD11c+, DEC205+)
and B cells (CD19+) and evaluated by flow cytometry analyses.
Tumorigenesis Model
Pathogen- free C57BL/6 mice (6–8wk old; Charles River) were
maintained in the West Los Angeles Veterans Affairs Animal
Research vivarium in accord with the institution’s animal review
board guidelines. All animal work was conducted in accord with
the Veterans Affairs Institutional Animal care and Use Committee
guidelines: id A3002-01. The Veterans Affairs Institutional Animal
care and Use Committee review board approved all the studies
involving animals in this manuscript. Animals exhibiting signs of
pain or meeting the endpoint criteria were euthanized immedi-
ately according to the accepted institution based protocol.
Mice were monitored daily for signs of distress from the tumor
burden and to ameliorate pain and suffering mice were euthanized
if the animals exhibited any clinical signs of distress, such as loss of
appetite, 10% cachexia weight loss, loss of mobility, restlessness,
depression, respiratory distress, tumor/skin breakdown, or failure
to groom. 3LL tumor cells (2.06105) were injected s.c. in the right
supra scapular area of C57BL/6 mice. Tumor volumes were
monitored by measuring two bisecting diameters of each tumor
with calipers. Tumor volumes were calculated using the formula:
V = 0.4ab2, (a = large diameter and b = small diameter). We have
used two doses for the in vivo depletion of MDSC based on
previous studies [100 mg/dose [17]] or [200 mg/dose] adminis-
tered every other day [18,19]. For studies described in this
manuscript we utilized the 200 mg/dose. One week following
tumor inoculation, mice with palpable tumors were injected i.p.
individually with anti-Gr-1-specific (200 mg/dose), or anti-Ly6G
specific (200 mg/dose), or isotype IgG2b Ab (200 mg/dose) every
48 hrs for 2 weeks. One, two or three weeks post tumor
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implantation, tumors, spleen, bone marrow and blood were
harvested for evaluation of the frequency and activity of leukocytic
populations by specific staining/flow cytometric analyses.
Orthotopic Model
Implantation of the tumors in the lung was performed as
previously described [20]. Briefly, 104 3LL cells in 25 ml sterile NS
diluent were injected by the transthoracic route of C57BL/6 mice
utilizing a tuberculin syringe with a 30-gauge needle in the left
lung under ketamine/xylazine anesthesia. One week following
tumor inoculation, a group of mice were sacrificed to confirm and
determine the baseline tumor burden before initiation of therapy.
One week following tumor inoculation, mice were individually
treated with control isotype or anti-Gr1Ab (200 mg/dose) via i.p.
route every 48 hrs for 4 weeks. Five weeks following tumor
implantation, lungs were perfused and harvested for evaluation of
tumor burden by H&E staining of tumor sections. Tumor burden
was evaluated in a single cell suspension of lung tumor digests by
EpCam staining of tumor cells followed by flow cytometric
evaluation. A total of 20,000 events were acquired on the
FACSCanto flow cytometer and data analyzed by the FCS
Express 3 software.
Vaccination Model
3LL-OVA tumor cells (2.06105) were injected s.c. in the right
supra scapular area of C57BL/6 mice. The vaccine consisted of
bone marrow adherent cells (BMA) that had been pulsed with
OVA protein. Briefly, BMA cells were pulsed with OVA protein
(2.5 mg/ml) in CM at 37uC in an incubator with a humidified
atmosphere containing 5% CO2 in air for 6 hrs. Cells were
washed in PBS twice and resuspended in normal saline (0.16106
in 200 ml/mouse) and administered by s.c. injection on the left
contra-lateral flank of the tumor implantation on days 7 and 14
post tumor inoculation. Groups included: (i) Diluent, (ii) BMA-
OVA, (iii) BMA-OVA + isotype and (iv) BMA-OVA + anti-Gr1.
Seven-days post tumor inoculation, the isotype or anti-Gr1 Ab
(200 mg/dose) were administered every 48 hrs for 2 weeks. Tumor
burden was monitored as described above and H&E or
immunohistochemistry (IHC) staining was performed on the
tumor sections. Treated mice that had completely rejected the
3LL-OVA tumors were re-challenged with 3LL-OVA tumor cells
(26105) on the left flank and monitored for tumor growth.
Immunological Memory
Splenocytes from mice that had rejected the secondary tumor
challenge were monitored for T cell immune memory phenotype
by staining for T cell memory surface markers CD44, CD69 and
intracytoplasmic IFNc with or without stimulation with OVA
protein (2.5 mg/ml overnight) in vitro. IFNc secreted by spenocytes
(56106) in the culture supernatant was quantified by ELISA and
CD4 and CD8 T cell IFNc or IL-10 production was quantified by
staining/flow cytometry. Splenocytes from naı¨ve mice served as
controls.
Antigen Processing and Presentation Assay
DC 2.4 or BMA or a single cell suspension of tumor digest (5–
106104 c/well) from controls, anti-Gr1 or anti-Ly6G treated
tumor bearing mice were co-cultured with OVA protein (2.5 mg/
ml) and the MHC Class I restricted CD8 T cell line B3Z (105 c/
well) in CM in triplicate wells of a 96-well plate for 24 hrs. IL-2
secreted by the activated CD8 T cells in the supernatant was
quantified by ELISA.
Flow Cytometry
Flow cytometry was performed for the following T cell surface
markers CD3, CD4, CD8, CD69 on single cell suspension of
splenocytes or tumor digests following treatment as described
above. Splenocytes and tumor cell digests were also evaluated for
the NK cells with the surface marker CD49b. CD4 T, CD8 T and
NK cells were individually evaluated for intracytoplasmic perforin,
granzyme, IFNc or IL-10. CD107a on T cells were evaluated by
cell surface staining/flow cytometry. For analyses of leukocytic
infiltrates in the tumor tissue, tumors were mechanically dissoci-
ated on a wire mesh by crushing with a 10 ml syringe and
incubated in tissue digestion buffer at 37uC for 25 min. The cells
were filtered through 70 mm nylon strainers (BD Biosciences,
Bedford, MA), stained with specific markers and analyzed by flow
cytometry. Samples were acquired on a FACSCanto (BD
Biosciences/FACSCalibur flow cytometer (Becton Dickinson,
San Jose, CA) in the University of California, Los Angeles,
Jonsson Cancer Center Flow Cytometry Core Facility. A total of
10,000 to 25,000 events were acquired and cells staining positive
within the total live cell population were analyzed using FCS
Express 3 (De Novo Software, Canada). Cells incubated with
irrelevant isotype-matched antibodies and unstained cells served as
controls.
CFSE Based Cytolysis Assay
Total cytolytic T cell activity in the spleen against parental 3LL
tumor cells or syngeneic B16 melanoma cells were evaluated
following treatment with anti-Gr1 or anti-Ly6G Ab on day 21 post
tumor inoculation. Tumor targets were labeled with CFSE at dose
(1 mM) in PBS for 15–20 mins according to the manufacturer’s
instructions. After washing, the labeled targets were incubated
with T cells purified from spleens using T cell columns (R&D), and
cytolytic activities were evaluated against autologous 3LL tumor
cell line and the syngeneic control B16 melanoma tumor cell line.
The purified splenic T cell effectors were co-cultured with tumor
cell targets (E:T of 10:1–5:1) for four hours in quadruplet wells in
a 96-well plate. Following a co-culture, cells were washed and
analyzed by flow cytometry. Decreases in the frequency and
intensity of CFSE labeled cells were used to calculate % of cytolysis
in tumor targets.
CFSE Labeling and T Cell Suppression Assays
T cells were purified from spleens using the T cell isolation
columns. Following two washes with PBS, purified T cells were
(26106 cells/ml) mixed with an equal volume of 10 mM CFSE
solution for 10 min. The reaction was terminated by the addition
of 10 volumes of cold RPMI 1640/10% FBS. Labeled cells
(16106 cells/ml) were washed twice with PBS/2% FBS. In a U-
bottom 96-well cell culture plate pre-coated with anti-CD3 Ab
(5 mg/ml), purified T cells (26105) were cultured in DMEM
supplemented with 10% FBS and anti-CD28 Ab (5 mg/ml) for 72–
96 h. To determine the impact of MDSC on T cell proliferation,
CFSE labeled T cells were co-cultured with purified Gr1 splenic
MDSC (2–46105) from 3LL bearing mice or naı¨ve mice and
changes in proliferation was assessed by flow cytometry. MDSC
were isolated from spleens by labeling the cell suspensions with rat
anti mouse Gr1 mAb (eBioscience), followed by magnetic antibody
cell separation using anti-rat microbeads (Miltenyi Biotec). The
isolated cells were .90% pure for CD11b+Gr1+ expressing
MDSC as determined by flow cytometry.
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Cytokine ELISA
The cytokines (IFNc, TNFa, IL-10 and IL-12) in splenocyte
culture supernatants or from spleen or tumor homogenates were
determined by ELISA and the plates read at the specified
wavelengths with a Microplate Reader (Amersham Biosciences,
Sunnyvale, CA).
Tumor Tissue Sectioning and Immunohistochemistry
To determine the extent of lymphocytes infiltrating the
tumors from the various treatment groups, C57BL/6 mice
bearing 7-day tumors were injected i.p. with Gr1-specific
(200 mg/dose) or Ly6G specific (200 mg/dose) or isotype IgG2b
Ab (200 mg/dose) every 48 hrs for 2 weeks. Non-necrotic
tumors were isolated and embedded in paraffin and serially
sectioned to 5-mm thickness. Sections were H&E or immune
stained for CD3 T lymphocytes or Gr1 expressing cells. To
determine apoptotic tumor cells, tumor sections were stained for
cleaved caspase 3. Antigen retrieval was accomplished with
sodium citrate (10 mmol/L, pH 6.0). Sections were blocked
with 10% normal goat serum, and probed with an antibody
against CD3, Gr1 or cleaved caspase 3. Primary antibodies
were incubated overnight at 4uC. After incubation with
secondary antibody (Vector Laboratories), staining was de-
veloped using DAB substrate kit for Peroxidase (SK-4100,
Vector Laboratories). Counter-stain was achieved with hema-
toxylin. The slides were observed under 1X71 Olympus
Fluorescence microscope attached to a CCD camera. The
images were acquired with 10X, 20X and 60X objectives using
the Image Pro software.
Apoptosis
To determine the extent of tumor cell apoptosis, a single cell
suspension of the tumor tissues were stained using a PI/Annexin
V-FITC apoptosis detection kit (BD Pharmingen) according to the
manufacturer’s instruction and the percentage of apoptotic tumor
cells (gated on CD452 cells) were analyzed by flow cytometry.
Total RNA Preparation, cDNA Synthesis and Real-time
QPCR
Mice bearing seven-day old tumors were treated with isotype,
anti-Gr1 or anti-Ly6G Ab and 2 week following treatment,
tumor tissues were quantified for Caspase 8, Angiopoietin1,
Angiopoietin2, VEGF-a, CXCL2, CXCL5, CXCL9, CXCL10 and
CXCR3 gene expression using a SYBR Green Quantitative PCR
Kit in the iCycler (Bio-Rad) and corrected with the b-actin
housekeeping control gene. For QPCR analyses, RNA was
isolated using a Qiagen kit. The cDNA was prepared with a kit
(BioRad) according to the manufacturer’s instructions. Amplifi-
cations were done in a total volume of 25 ml for 40 cycles of
15 s at 95uC, 20 s at 60uC, and 30 s at 72uC. Primer sequences
were as follows: b-actin F, 59- CCACAGCTGAGAGGGAAATC
-39 and R, 59- TCTCCAGGGAGGAAGAGGAT -39; Caspase 8
F, 59- TGCTTGGACTACATCCCACAC-39 and R, 59-
GTTGCAGTCTAGGAAGTTGACC -39; Ang-1 F, 59-
TCTCATGCTAACAGGAGGTTGGTG -39 R, 59-GGAT-
CATCATGGTGGTGGAACGTA-39; Ang-2 F, 59- CAA-
GAGCTCGGTTGCTATCCGTAA-39 R, 59 GTCCATGTCA-
CAGTAGGCCTTGAT39; VEGF-a F, 59-
TGTACCTCCACCATGCCAAGT-39 R, 59- CGCTGGTA-
GACGTCCATGAA-39; CXCL5 F, 59- GGTCCACAGTGCCC-
TACG-39 R, 59- GCGAGTGCATTCCGCTTA-39; CXCL2 F,
59- AGTGAACTGCGCTGTCAATG -39 R, 59- GA-
GAGTGGCTATGACTTCTGTCTG-39; CXCL9 F, 59-
GCACGATCCACTACAAATCCC-39 R, 59-
GGTTTGATCTCCGTTCTTCAGT-39; CXCL10 F, 59-
CCAAGTGCTGCCGTCATTTTC-39 R, 59-
TCCCTATGGCCCTCATTCTCA-39; and CXCR3 F,
TCTCCCTACGATTATGGGGAAAA-39 and R, 59-
GGTTCTGTCAAAGTTCAGGCT-39.
Statistical Analyses
All data are presented as mean 6 SE. Statistical analysis was
performed using Prism (GraphPad Software). We used analysis of
variance for data with multiple groups, unpaired Student’s t-test
for dual comparison. P values ,0.05 were considered significant.
Results
MDSC Increased in Tumor Bearing Mice as a Function of
Tumor Growth
To determine the impact of 3LL tumor growth on the
frequency of MDSC, non necrotic tumors, blood, spleen or BM
were evaluated for Gr1+CD11b+ expression (days 7, 14 and 21
post tumor inoculation). Similar to findings of MDSC increase
in cancer patients [4,5], there were increased MDSC frequency
in 3LL tumor bearing mice. MDSC frequency increased in the
blood (2–4 fold), spleen (2.6–4 fold) and BM (1.5–2 fold) of
tumor bearing mice in comparison to control naive mice
(Figure 1A–B). Day-7 tumors had a lower frequency of
MDSC in comparison to days 14 and 21. The frequency of
MDSC in the tumor digests was further enhanced on day 21 (3
fold) compared to day 14 tumors (Figure 1A–B). To confirm
the immune suppressive effects of MDSC, we evaluated the
function of splenic MDSC from tumor bearing mice on the
inhibition of DC2.4 APC activity or T cell proliferation. For the
in vitro DC APC activity evaluation, we selected cell numbers of
DC and OVA specific CD8 T cells that produced high levels of
IL-2 under the assay conditions to provide clear differences in
IL-2 levels in the presence or absence of MDSC. MDSC from
naı¨ve mice did not suppress DC APC activity. Although MDSC
from day 7 tumor bearing mice suppressed DC APC activity,
the suppressive effect was lower in comparison to MDSC from
day 14 and 21 tumor bearing mice (Figure 1C). In addition,
MDSC from naı¨ve mice did not inhibit anti-CD3/CD28
stimulated CFSE labeled T cell proliferation and MDSC from
day 7 tumor bearing mice had a lower suppressive capacity on
T cell proliferation in comparison to MDSC from day 14 and
21 tumor bearing mice [Figure 1D(i–ii)].
Figure 1. MDSC increased in tumor bearing mice as a function of tumor growth. 1A, representative FACS plots for MDSC in blood, BM,
spleen and tumor of 3LL tumor bearing mice (Days 7, 14 and 21) in comparison to naive mice. 1B, FACS data for MDSC frequency in blood, BM, spleen
and tumor (Days 7, 14 and 21) represented as bar graphs (*p,0.05 day 14 vs day 7), (**p,0.005 day 21 vs day 14). 1C, MDSC from tumor bearing
mice suppress DC2.4 APC activity to activate the antigen specific CD8 T cells to secrete IL-2 (*p,0.05 with MDSC compared to without MDSC), 1D,
MDSC from tumor bearing mice suppress anti-CD3/CD28 stimulated CFSE labeled T cell proliferation. 1Di, Representative FACS CFSE intensity plots
for T cell proliferation (with or without MDSC). 1D-ii, Geometric mean (GM) for T cells CFSE intensity represented as bar graphs. (*p,0.05 with MDSC
vs without MDSC), values reflect mean 6 standard error of the mean (SEM), n = 8 mice per group.
doi:10.1371/journal.pone.0040677.g001
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Figure 2. MDSC depletion reduced 3LL tumor burden, increased APC activity and augmented splenic T cell cytolytic function. 2A,
Changes in tumor volume following anti-Gr1 or anti-Ly6G Ab mediated MDSC depletion. 2B, Changes in tumor weights for MDSC depleted and
control groups (day 21). 2C, Representative FACS plots and bar graphs for frequency of CD11b+Gr1+ MDSC in tumor following anti-Gr1 or anti-Ly6G
Ab treatment. 2D, Representative FACS plots for frequency of CD11b+Gr1+ MDSC in tumor following anti-keratin Ab treatment. 2E, Representative
APC activity in tumor to activate the CD8 antigen specific T cells to secrete IL-2 following anti-Gr1, anti-Ly6G, isotype control Ab and diluent
treatment. 2F, CD107a activation marker expression on T cells in tumor following MDSC depletion. 2G, Total purified splenic T cell cytolysis against
3LL parental tumor (E:T 10:1, 5:1) for the MDSC depleted groups and isotype controls. There were no differences in T cell cytolysis of parental 3LL cells
between the diluent and the isotype control group (data not shown). There were no changes in T cell cytolysis against the non related B16 tumors
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MDSC Depletion Reduced 3LL Tumor Burden, Increased
APC Activity and Augmented the Cytolytic Function of T
Cell Effectors
To determine the impact of MDSC on tumor burden, APC and
T cell effectors, we depleted MDSC in 3LL tumor bearing mice
utilizing anti-Gr1 or anti-Ly6G Ab. In comparison to controls,
MDSC depletion led to the inhibition of tumor volume
(Figure 2A), tumor weights (8 fold-day 21) (Figure 2B) and
a reduction in Gr1 expressing cells (4–5 fold) in the tumor
(Figure 2C) and systemically in the blood (2 fold), spleen (2.4–7
fold) and BM (1.3–2.9 fold) (data not shown). To evaluate the
specificity of antibody mediated MDSC depletion, a negative
control anti-keratin Ab was administered on the same dose and
schedule as the MDSC depletion antibodies. The anti-keratin Ab
treatment did not impact the Gr1 expressing MDSC frequency
(Figure 2D). MDSC depletion increased APC activity in the
tumor whereas the controls had reduced APC activity on days 14
and 21 in comparison to day 7 (Figure 2E). Compared to
controls, MDSC depletion led to an increase in the frequency of
activated CD3 CD107a T effector cells (Figure 2F) and systemic
splenic T cell specific cytolysis against CFSE labeled parental
tumor [E:T at 10:1, (1.5–2 fold) and at 5:1, (2 fold)] (Figure 2G).
There were no changes in T cell cytolysis against the non related
B16 tumors between the MDSC depleted groups and controls
(data not shown).
MDSC Depletion Augmented the Frequency and
Function of NK and T Cell Effectors and Reduced 3LL
Lung Metastases
NK and T cell effectors are decreased in the tumor bearing
state. We determined the impact of MDSC depletion on these
effectors in 3LL tumor bearing mice. In comparison to controls,
MDSC depletion led to small diffused tumors by H&E staining
with increased T cell infiltrates and reduced Gr1 expressing cells
(Figure 3A). While the mice in the control groups had visible
lung tumor metastases, MDSC depleted groups did not show any
visible lung metastases (Figure 3B). MDSC depletion increased
the frequency of NK (1.6–3 fold), CD3 (1.5–3.3 fold), CD4 (1.5
fold), CD8 (1.5–2 fold) but did not alter the frequency of F480+
macrophages or CD11c+ DC (Figure 3C). There were no
changes in FoxP3+CD4CD25+ T cells in the tumor site and
periphery following MDSC depletion with anti-Gr1 or anti Ly6G
treatment (data not shown). In comparison to controls, MDSC
depletion increased the frequency of activated: (i) NK cells
expressing IFNc (4–6 fold), perforin (3–10 fold) and granzyme
(2–4 fold) (Figure 3D) and (ii) CD8 expressing IFNc (1.5–3 fold),
perforin (2–2.5 fold) and granzyme (2.5–6 fold) but reduced IL-10
(2.4–3.6 fold) expression (Figure 3E). There were increased IFNc
(1.6–2 fold), IL-12 (3 fold), and TNFa (10 fold) but reduced IL-10
(19–39 fold) in the tumors following MDSC depletion in
comparison to controls (Figure 3F).
MDSC Depletion Augmented Tumor Cell Apoptosis,
Increased Anti-angiogenic but Reduced Pro-angiogenic
Marker Expression in Tumors
Based on the increased frequency and activation profile of NK
and T cells effectors in the tumor following MDSC depletion, we
evaluated apoptosis of tumor cells by quantifying the expression of
cleaved caspase 3 by IHC in the tumor sections and the % of
annexin V/PI +ve stained cells on the non CD45 expressing tumor
cell population by flow cytometric analysis. IHC of the tumor
sections revealed increased tumor staining of cleaved caspase 3
(Figure 4A) and increased % of annexin V/PI +ve apoptotic
tumor cells (early: 2.5–5.9 fold, late: 1.9–2.4 fold) (Figure 4B) in
the MDSC depleted groups compared to controls. Similarly the
tumors from the MDSC depleted group had: enhanced caspase 8
expression (6.4–15 fold) (Figure 4C), decreased MECA 32
endothelial cell marker expression (2 fold) and increased T cell
CXCR3 expression (1.5–2 fold) by flow cytometry (Figure 4D),
decreased pro-angiogenic (VEGF-a, CXCL2, CXCL5, Ang1 and
Ang2) (Figure 4 E–F) but increased anti-angiogenic (CXCL9
and CXCL10) (Figure 4G) and CXCR3 (Figure 4H) expres-
sion in the tumors by RTQPCR. The antitumor efficacy of
MDSC depletion with anti-Gr1 antibody was determined in the 7-
day established orthotopic 3LL lung cancer model. Similar to the
findings in the s.c. model, MDSC depletion inhibited tumor
burden by 7-fold compared to controls (Figure 5A–B). In the
control groups, there were 7–9% decrease in the average body
weight at the end of the experimental duration but no significant
weight change was observed in the anti-Gr1 treatment group.
Similar to what was observed in the s.c model; we found increased
NK and T cell effectors in the lung following treatment (data not
shown).
MDSC Depletion Enhanced Therapeutic Vaccination
Responses
The impact of MDSC depletion on therapeutic vaccination
responses was evaluated utilizing 3LL OVA tumor cells and BMA
cells pulsed with the OVA protein served as the vaccine. 14-day
BMA culture (Figure 6A) propagated in RP-20 were evaluated
by cell surface staining/flow cytometry analyses. BMA culture is
comprised of a heterogeneous population of monocytes (51%-
CD11b+), macrophages (14%-F480+CD11b+), DC (10%-CD11c+,
DEC205+), stromal cells (20%-CD452/CD11b2/CD44+/
CD342) and B cells (8%-CD19+) and cell surface phenotype
(MHC Class I (94%), MHC Class II (53%), CD80 (57%) and
CD86 (37%) necessary for APC activity. BMA cells efficiently
processed and presented the OVA protein to activate the CD8 T
OVA specific cell line to secrete IL-2 (Figure 6B). Mice bearing
3LL-OVA were vaccinated with: (i) Diluent, (ii) BMA-OVA, (iii)
BMA-OVA + Isotype and (iv) BMA-OVA + anti-Gr1 Ab.
Compared to controls, therapeutic vaccination with BMA-OVA
substantially inhibited tumor growth rate without eradicating the
tumors (7 fold) (Figure 6C). In comparison to controls, the
combination of BMA-OVA + anti-Gr1 Ab had the most
pronounced tumor growth inhibition (20 fold) (Figure 6C) and
H&E section revealed increased leukocytic infiltrates and in-
creased tumor staining of cleaved caspase 3 (Figure 6D). 50% of
mice in the combined BMA-OVA plus anti-Gr1 Ab treatment
group completely rejected their primary tumors and a rechallenge
dose of 3LL-OVA tumor cells (26105) (Table 1). Mice that had
rejected a tumor rechallenge were evaluated for T cell memory
and T cell activation phenotype following splenic stimulation with
OVA protein in vitro. In comparison to naı¨ve control, mice that
had rejected tumors in the vaccination plus anti-Gr1 treatment
had increased: splenic production of IFNc (Figure 6E) and
frequency of IFNc producing CD4 and CD8 memory (CD44) and
activation (CD69) marker expressing T cells (Figure 6F).
Following splenic stimulation with OVA protein, memory T cells
between the MDSC depleted groups and controls (data not shown). Data in all panels are representative of 2-3 independent experiments (Data, mean
6 SEM, p values: compared to controls *p,0.05, **p,0.005, n = 6 mice/group.
doi:10.1371/journal.pone.0040677.g002
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Figure 3. MDSC depletion augmented the frequency and function of NK and T cell effectors and reduced 3LL lung metastases in
tumor bearing mice. 3A, H&E and IHC for T cells or GR1 expressing cells in tumor tissues following MDSC depletion or control treatments. 3B, H&E
of lung sections to evaluate lung metastasis following MDSC depletion. 3C, Frequency of tumor infiltrates (CD3, CD4, CD8, CD11c, F480 or CD49b),
3D, NK cells expressing IFNc, perforin and granzyme, 3E, CD8 expressing IFNc, perforin and granzyme but reduced IL-10 expression analyzed by flow
cytometry. 3F, Tumor cytokine expression (IFNc, IL-12, TNFa and IL-10) following MDSC depletion. (Data, mean 6 SEM, *p,0.05 compared to
controls, n = 8 mice/group).
doi:10.1371/journal.pone.0040677.g003
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Figure 4. MDSC depletion augmented the tumor cell apoptosis and increased anti-angiogenic but reduced pro-angiogenic marker
expression in tumors. 4A, IHC for cleaved caspase 3 in tumor sections following MDSC depletion. The arrows are indicative of cleaved caspase 3
staining. 4B, AnnexinV and PI staining in tumor digests by flow cytometry. 4C, Relative caspase 8 expression by QRTPCR normalized with b-actin
expression in tumor tissues. 4D, Endothelial MECA 32 cell marker expression and total T cell CXCR3 expression in tumors by flow cytometry. 4E–H,
Relative pro-angiogenic and anti-angiogenic marker expression in tumors by QRTPCR normalized by b-actin. MDSC depletion decreased pro-
angiogenic (VEGF-a, CXCL2, CXCL5, Ang1 and Ang2) (4E–F) but increased anti-angiogenic (CXCL9 and CXCL10) (4G) and CXCR3 (4H) expression in
the tumors. (Data, mean 6 SEM, p values: compared to controls *p,0.05, n = 8 mice/group).
doi:10.1371/journal.pone.0040677.g004
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had increased production of IFNc from the vaccination plus anti-
Gr1 treatment compared to naı¨ve controls (Figure 6G). The
splenic T cell IL-10 expression pattern following OVA stimulation
in vitro from mice that had rejected a rechallenge did not change in
comparison to T cells from naı¨ve control (data not shown).
Discussion
With the existing therapeutic efforts, the long term survival for
lung cancer patients remains low, thus novel therapeutic strategies
are needed. Cancer immunotherapy offers an attractive therapeu-
tic option. The concept of immune approaches against lung cancer
remains attractive because although surgery, chemotherapy, and
radiotherapy alone or in combination produce response rates,
relapse is unavoidable. Thus, strategies that harness the immune
system against tumors have the potential for long term cancer free
survival. Immune therapy for lung cancer has potential; however,
there have been limited Phase III trial-documented improvement
in survival [21]. Tumor-induced immune suppression may
contribute to the limited efficacy of the approaches. Many tumors,
including lung cancer, have the capacity to promote immune
tolerance and escape host immune surveillance. Tumors utilize
numerous pathways to inhibit immune responses, including the
elaboration of immune inhibitory cytokines as well as inducing
host cells to release immune inhibitors [22,23]. In addition to these
mechanisms, immune suppression through MDSC has a crucial
role in promoting tumor progression. We hypothesized that
activating immune cells through therapeutic vaccination with
simultaneous disruption of MDSC mediated regulatory mechan-
isms that limit immune responses will improve the antitumor
activity in lung cancer. To test our hypothesis, we evaluated the
efficacy of a combined immune based approach consisting of
a therapeutic vaccine and MDSC depletion on the impact of
immune activation and antitumor activity in an established murine
tumor model.
To initiate antigen specific responses in vivo, we utilized a cellular
vaccine, consisting of BMA cells pulsed with the model OVA
antigen expressed by the OVA modified 3LL tumor cells. The
BMA cells were pulsed with the OVA antigen to allow for antigen
processing and presentation and then injected s.c. on the
contralateral flank of the established tumor to initiate antigen
specific anti tumor immune responses. The BMA cells expressed
cell surface phenotype for APC activity and efficiently processed
and presented antigens to antigen specific CD8 T cells in vitro as
well as induced antitumor responses in vivo. In contrast, although
lung cancer cells express tumor antigens, the limited expression of
MHC antigens, defective transporter associated with antigen
processing (TAP) and lack of co-stimulatory molecules make them
ineffective APCs [24].
To circumvent MDSC mediated immune suppression in the
tumor microenvironment, we utilized monoclonal antibodies (anti-
Gr1 or anti-Ly6G) to deplete MDSC. We have found that as
tumors progress, the frequency and activity of MDSC are
enhanced in the tumor microenvironment and systemically. Our
results show about 40% of tumor infiltrates are MDSC that have
the capacity to turn off the functional antitumor activities of APC,
NK and T cell effectors. The tumor cell inoculations in this study
did not include matrigel mixed with tumor cells but rather tumor
cells in saline. Hence the increase in MDSC in the tumor
microenvironment and systemically is due to progressive tumor
growth. However injection of matrigel formulations that release
MDSC chemotactic factors also have the potential to recruit
MDSC. The inadequate function of the host immune system
through the down regulation of APC, NK and T cell effectors as
well as the elaboration of effector molecules is one of the major
mechanisms of tumor immune escape. Similar to increases of
MDSC in cancer patients, our data demonstrate that 3LL tumor
bearing mice had increased frequency of MDSC in the tumor,
blood, spleen and BM as a function of tumor growth. These
Figure 5. MDSC depletion inhibited tumor burden in the 3LL orthotopic lung tumor model. 5A, Representative H&E of lung tumor
sections following MDSC depletion and controls; arrows indicative of tumor. 5B, Tumor burden evaluated by cell surface staining for Epcam in a single
cell suspension of tumor digests and quantified by flow cytometry. (Data, mean 6 SEM, p values: compared to controls *p,0.05, n = 8 mice/group).
doi:10.1371/journal.pone.0040677.g005
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Figure 6. MDSC depletion enhanced vaccination responses. 6A, 14-day BMA culture propagated in CM. 6B, BMA cells processed and
presented the OVA protein to activate the CD8 T OVA specific cell line to secrete IL-2. 6C, Tumor volume following vaccination (groups: Diluent, BMA-
OVA, BMA-OVA + Isotype and BMA-OVA + anti-Gr1 Ab). 6D, H&E and IHC for cleaved caspase 3 in tumor tissues following vaccination. Arrows
indicative of leukocytic infiltrates and cleaved caspase 3 staining in the tumors. 6E–G, Flow cytometry analyses of splenic T cell memory and
activation markers from mice that had rejected tumors in the vaccination plus anti-Gr1 treatment group in comparison to non tumor bearing naı¨ve
controls; 6E, Splenic production of IFNc, 6F, Frequency of IFNc producing CD4 and CD8 memory (CD44) and activation (CD69) marker expressing T
cells. 6G, Geometric Mean of IFNc producing memory T cells from vaccination plus anti-Gr1 treatment following stimulation with OVA protein
compared to naı¨ve controls. (Data, mean 6 SEM, p values: compared to controls *p,0.05, n = 8 mice/group).
doi:10.1371/journal.pone.0040677.g006
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MDSC functionally suppressed T cell proliferation and APC
activities in vitro.
The central importance of functional APC in the immune
response against cancer has been well defined [25]. The study
revealed that even highly immunogenic tumors require host APCs
for antigen presentation. Thus, host APC, rather than tumor cells,
present tumor antigens. This is consistent with a study indicating
that CD8+ T-cell responses can be induced in vivo by professional
APC that present exogenous antigens in a MHC I-restricted
manner [26]. This has been referred to as cross-priming or
representation and may be critical for effective antitumor
responses [27]. However, in tumor-bearing hosts, there is a state
of T-cell unresponsiveness [28,29,30]. T cell non responsiveness to
specific antigens has been shown to be an early event in tumor
progression in animal models of cancer and in cancer patients
[31]. The cellular mechanisms that lead to the induction of the
tolerogenic state are not well understood. The dominant
mechanism underlying the development of antigen-specific T-cell
unresponsiveness is thought to be through tumor-antigen proces-
sing and presentation by APC [32]. Although T-cell tolerance in
cancer has been shown to be mediated by host APC, [25,32] the
nature of these APC have not been clear. Recent studies provide
evidence that MDSC may represent a population of APC
responsible for induction of antigen-specific CD8 T-cell tolerance
in cancer [33,34]. The tumor microenvironment has immune
suppressive mediators such as PGE2, TGF-b, IL-10, VEGF, GM-
CSF, IL-6, S100A8/A9 and SCF that recruit and/or activate
MDSC [35,36,37]. Solid tumors contain a significant proportion
of MDSC that maintain an immune suppressive network in the
tumor microenvironment.
The impact of MDSC depletion on the APC, T and NK
effector activities was evaluated to determine if antitumor innate
and adaptive T cell activities could be restored in lung cancer.
Broad depletion of MDSC by antibodies that targeted the Gr1 or
Ly6G led to decreased MDSC population in the tumor and
systemically in the blood, spleen and BM. The APC activity in the
tumor was reduced as the tumors progressed, however, MDSC
depletion led to increased APC activity in the tumor. Consistent
with an increase in APC activity with MDSC depletion, there were
increased frequency and activity of NK and T cell effectors in the
tumor in comparison to controls. The increased activity of NK cell
effectors is significant since these innate immune cells are the first
line of defense against tumors and inhibit tumor growth in a non-
MHC restricted manner and without prior sensitization to an
antigen [38,39]. CTL and NK cells possess similar cytolytic
mechanisms including secretion of perforin and granzyme. Our
data indicates that the activated NK and T cell effectors had
increased expression of the cytolytic markers granzyme and
perforin as well as an increase in IFNc but reduced IL-10. The
cytokine signature of increased IFNc and reduced IL-10 in the
tumor further facilitates antitumor activity. While IFNc induces
anti-angiogenesis through the induction of CXCL9 and CXCL10
[20], reduction in IL-10 can improve APC activity and promote
Type I responses [40]. This data indicates that while 3LL tumor
growth increased MDSC and reduced APC, NK, and T cell
activities, MDSC depletion released the brakes on the functional
activities of APC, NK and T cell effectors. In accord with the
increased NK and T cell activities, there was an increase in the
frequency of apoptotic tumor cells and a concomitant inhibition in
tumor burden and migration of tumor cells from the primary
tumor site to the lung. The reduction in tumor growth and
abrogation in tumor cell migration may be explained by an
increase in the frequency of activated T and/or NK effector
mediated tumor apoptosis and/or T or NK IFNc mediated anti-
angiogenesis. Based on our observations on increased T and NK
cell IFNc production in the tumor, we evaluated the angiogenic
profiles in the tumor. The anti-angiogenic (CXCL9, CXCL10)
and pro-angiogenic markers (VEGFa, CXCL2, CXCL5, Angio-
poietin 1 and Angiopoietin 2) were quantified in the tumor by
RTQPCR. Following MDSC depletion, the anti-angiogenic
chemokines CXCL9 and CXCL10 were increased but the pro-
angiogenic cytokines VEGFa, Angiopoietin1, Angiopoietin2,
CXCL2 and CXCL5 were markedly reduced. Accompanying
this profile was a reduction in the endothelial markers MECA 32
in the tumor but an increase in CXCR3 expression. This data
indicates that following MDSC depletion there is an influx of IFNc
producing activated T and NK cells that promote angiostasis in
the tumor microenvironment by altering the balance of pro and
anti angiogenic chemokines. This further suggests that MDSC
depletion not only improves APC, NK and T cell immune
activities but promotes anti angiogenesis in the tumor that is more
effective at controlling tumor growth.
Based on increases in the APC, NK and T cell activities
following MDSC depletion, therapeutic vaccination responses
were evaluated in vivo. In comparison to controls, therapeutic
vaccination with BMA-OVA led to decreased tumor burden
without complete eradication of the tumors. However following
the depletion of MDSC with anti-Gr1 in combination with BMA-
OVA vaccine, treated mice had the most substantial reduction in
tumor burden with 50% of the mice completely eradicating the
tumors and the remainder of mice with a 20 fold reduction in
tumor burden in comparison to control. The data indicates that
therapeutic vaccination is more effective when combined with
MDSC depletion. Long term immunological memory was induced
in these mice that were efficient in rejecting a secondary tumor
challenge. Flow cytometric evaluation of spleens of mice that had
rejected a secondary tumor rechallenge showed an enhancement
in the CD4+CD44+ and CD8+CD44+ T cell memory markers as
well as an enhanced secretion of IFNc by memory T cells in
response to OVA stimulation in vitro. Our findings demonstrate
that to engage a coordinated and effective attack against tumors,
multiple components of the immune system need to evolve in
parallel that require mechanisms leading to immune cell activation
with the coordinated disruption of the regulatory mechanisms that
limit antitumor immune responses.
Taken together, our data indicate that MDSC depletion
reprograms the tumor niche by altering the inflammatory
infiltrates in the tumor microenvironment making it permissive
for immune destruction of tumors. The benefit of MDSC
depletion is further augmented when combined with therapeutic
vaccination leading to tumor eradication and immunological
memory. Targeting MDSC can improve antitumor immune
responses suggesting a broad applicability of combined immune
based approaches against a wide range of solid malignancies. This
Table 1. 50% of mice in the BMA-OVA + anti-Gr1 Ab
treatment group completely rejected their primary tumors




BMA-Ova + Isotype 0/8
BMA-Ova + Anti-GR1 4/8
doi:10.1371/journal.pone.0040677.t001
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multifaceted approach may prove useful for cancer therapeutics
against solid tumors where MDSC play a major role in tumor
immune evasion. These results are encouraging and warrant
further evaluation of combined MDSC targeting with vaccination
approaches for the full therapeutic potential of this strategy in lung
cancer and other malignancies.
Author Contributions
Conceived and designed the experiments: SS MKS SD. Performed the
experiments: MKS LZ SS MH UK MFJ. Analyzed the data: SS MKS SD
MHW JML DE RS. Contributed reagents/materials/analysis tools: SS SD
MHW. Wrote the paper: SS MKS SD.
References
1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Ca 60: 277–300.
2. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators
of the immune system. Nat Rev Immunol 9: 162–174.
3. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, et al. (2010) Myeloid-
derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol
22: 238–244.
4. Young MR, Wright MA, Pandit R (1997) Myeloid differentiation treatment to
diminish the presence of immune-suppressive CD34+ cells within human head
and neck squamous cell carcinomas. J Immunol 159: 990–996.
5. Kusmartsev SA, Kusmartseva IN, Afanasyev SG, Cherdyntseva NV (1998)
Immunosuppressive cells in bone marrow of patients with stomach cancer. Adv
Exp Med Biol 451: 189–194.
6. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo MA, et al. (1989)
Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing
mice. Int J Cancer 44: 307–314.
7. Kusmartsev SA, Ogreba VI (1989) Suppressor activity of bone marrow and
spleen cells in C57Bl/6 mice during carcinogenesis induced by 7,12-
dimethylbenz(a)anthracene. Eksp Onkol 11: 23–26.
8. Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S
(1992) T-cell subsets and suppressor cells in human bone marrow. Blood 80:
3242–3250.
9. Young MR, Wright MA, Matthews JP, Malik I, Prechel M (1996) Suppression of
T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells
producing transforming growth factor-beta and nitric oxide. J Immunol 156:
1916–1922.
10. Sugiura K, Inaba M, Ogata H, Yasumizu R, Inaba K, et al. (1988) Wheat germ
agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow
have potent natural suppressor activity. Proc Natl Acad Sci U S A 85: 4824–
4826.
11. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, et al. (1995)
Involvement of nitric oxide in bone marrow-derived natural suppressor activity.
Its dependence on IFN-gamma. J Immunol 155: 15–26.
12. Brooks JC, Hoskin DW (1994) The inhibitory effect of cyclophosphamide-
induced MAC-1+ natural suppressor cells on IL-2 and IL-4 utilization in MLR.
Transplantation 58: 1096–1103.
13. Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-
derived suppressor cells induce anergy of NK cells through membrane-bound
TGF-beta 1. J Immunol 182: 240–249.
14. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can
present exogenous antigens on both MHC class I and class II molecules.
J Immunol 158: 2723–2730.
15. Shastri N, Gonzalez F (1993) Endogenous generation and presentation of the
ovalbumin peptide/Kb complex to T cells. J Immunol 150: 2724–2736.
16. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, et al. (1995)
Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-
monocyte colony-stimulating factor, and interferon-gamma) on generation of
primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell
Immunol 165: 183–192.
17. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, et al. (2009) Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘‘N1’’ versus ‘‘N2’’ TAN.
Cancer Cell 16: 183–194.
18. Seung LP, Rowley DA, Dubey P, Schreiber H (1995) Synergy between T-cell
immunity and inhibition of paracrine stimulation causes tumor rejection. Proc
Natl Acad Sci U S A 92: 6254–6258.
19. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, et al. (2011) Gr-1+ CD11b+
myeloid-derived suppressor cells suppress inflammation and promote insulin
sensitivity in obesity. JBC 286: 23591–23599. Epub 22011 May 23518.
20. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, et al. (2009) IL-7 promotes
CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol
182: 6951–6958.
21. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, et al. (2005)
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV
non-small-cell lung cancer. J Clin Oncol 23: 6674–6681.
22. Chouaib S, Assellin-Paturel C, Mami-Chouaib F, Caignard A, Blay J (1997) The
host-tumor immune conflict: from immunosuppression to resistance and
destruction. Immunology Today 18: 493–497.
23. Smyth MJ, Trapani JA (2001) Lymphocyte-mediated immunosurveillance of
epithelial cancers? Trends Immunol 22: 409–411.
24. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, et al. (1993)
Identification of human cancers deficient in antigen processing. J Exp Med 177:
265–272.
25. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, et al. (1994)
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor
antigens. Science 264: 961–965.
26. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from
apoptotic cells and induce class I- restricted CTLs. Nature 392: 86–89.
27. Bevan MJ (1995) Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp
Med 182: 639–641.
28. Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, et al.
(1998) Induction of antigen-specific T cell anergy: An early event in the course of
tumor progression. Proc Natl Acad Sci U S A 95: 1178–1183.
29. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, et al. (2003) Extra-lymphatic
solid tumor growth is not immunologically ignored and results in early induction
of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor
antigens. Cancer Res 63: 9007–9015.
30. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid
destruction by inducing T-cell tolerance. Nature 437: 141–146.
31. Gabrilovich D, Pisarev V (2003) Tumor escape from immune response:
mechanisms and targets of activity. Curr Drug Targets 4: 525–536.
32. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, et al. (2001)
Cross-presentation of tumor antigens by bone marrow-derived antigen-
presenting cells is the dominant mechanism in the induction of T-cell tolerance
during B-cell lymphoma progression. Blood 98: 1070–1077.
33. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, et al. (2007) Altered
recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat
Med 13: 828–835.
34. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, et al. (2007)
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived
suppressor cells. Cancer Res 67: 11021–11028.
35. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking
inflammation and cancer. J Immunol 182: 4499–4506.
36. Pan PY, Wang GX, Yin B, Ozao J, Ku T, et al. (2008) Reversion of immune
tolerance in advanced malignancy: modulation of myeloid-derived suppressor
cell development by blockade of stem-cell factor function. Blood 111: 219–228.
37. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, et al. (2012)
Myeloid suppressor cells and immune modulation in lung cancer. Immunother-
apy 4: 291–304.
38. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, et al. (2007) NK cells and
cancer. J Immunol 178: 4011–4016.
39. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, et al. (2007)
Acquisition of murine NK cell cytotoxicity requires the translation of a pre-
existing pool of granzyme B and perforin mRNAs. Immunity 26: 798–811. Epub
2007 May 2031.
40. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, et al. (1999) T cell-derived
IL-10 promotes lung cancer growth by suppressing both T cell and APC
function. J Immunol 163: 5020–5028.
MDSC Depletion Enhance Vaccination Response
PLoS ONE | www.plosone.org 13 July 2012 | Volume 7 | Issue 7 | e40677
